About Ocimum Biosolutions
Ocimum Biosolutions is a life sciences RnD enabling company with three focus areas, BioIT (LIMS / Bioinformatics), BioMolecules, and BioResearch. Ocimum aims to deliver end to end genomic products and services out of three strategic locations worldwide, Indianapolis (United States), IJsselstien (The Netherlands), Hyderabad (India).
Missing: Ocimum Biosolutions's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Ocimum Biosolutions's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Ocimum Biosolutions Patents
Ocimum Biosolutions has filed 1 patent.
MicroRNA, Transcription factors, Muscarinic antagonists, MicroRNA precursor families, Disk file systems
MicroRNA, Transcription factors, Muscarinic antagonists, MicroRNA precursor families, Disk file systems
Latest Ocimum Biosolutions News
Jan 29, 2017
Ocimum Biosolutions Ltd Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 22:20 EST 28 Jan 2017 | BioPortfolio Reports Home » Topics » Bioscience » Latest News » Ocimum Biosolutions Ltd Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 Summary Ocimum Biosolutions Ltd Ocimum is a life science informatics company that provides solutions with data analysis services and BioIT consulting services. The company offers bio analytics, genomics data analysis services such as bioinformatics, gene expression , genomics databases, genotyping, next gen sequencing , and bioIT consulting services. It also offers genomics databases such as BioExpress, ToxExpress and others. The company's lab services include laser capture microdissection, nucleic acid isolation, gene, exon and miRNA expression, genotyping and copy number, sequencing, qRTPCR services and cloning services. Ocimum also provides diagnostic kits. The company partners with research institutes and biotechnology companies to offer its services. It has operational presence in India and the US. Ocimum is headquartered in Hyderabad, Telangana, India. Ocimum Biosolutions Ltd Pharmaceuticals Healthcare Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions. GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research. Scope Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector. Major Deals Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios. Business Description A brief description of the company's operations. Key Employees A list of the key executives of the company. Important Locations and Subsidiaries A list and contact details of key centers of operation and subsidiaries of the company. Key Competitors A list of the key competitors of the company. Key Recent Developments A brief on recent news about the company. Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay uptodate on the major developments affecting the company Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company. Related Biotechnology, Pharmaceutical and Healthcare News
Ocimum Biosolutions Web Traffic
Ocimum Biosolutions Rank
Ocimum Biosolutions Frequently Asked Questions (FAQ)
When was Ocimum Biosolutions founded?
Ocimum Biosolutions was founded in 2000.
Where is Ocimum Biosolutions's headquarters?
Ocimum Biosolutions's headquarters is located at 6th Floor, Reliance Classic, Gaithersburg.
What is Ocimum Biosolutions's latest funding round?
Ocimum Biosolutions's latest funding round is Other Investors.
Who are the investors of Ocimum Biosolutions?
Investors of Ocimum Biosolutions include Ficus Enterprises, International Finance Corporation, Kubera Partners and Kubera Cross-Border Fund.
Who are Ocimum Biosolutions's competitors?
Competitors of Ocimum Biosolutions include KIYATEC, HTG Molecular Diagnostics, WaferGen Bio-systems, ZyGEM, ProteinSimple and 10 more.
Compare Ocimum Biosolutions to Competitors
Harvard Bioscience acquires and distributes laboratory equipment and products for companies and institutions in the life sciences field.
Biocom works to drive public policy, build a network of industry leaders, create access to capital, introduce STEM education programs, and create value-driven purchasing programs.
Proteoplex is a spinout of Incyte Genomics and aims to provide the scientific community with key functional genomic and proteomic tools and services in the areas of Gene Expression, Protein Expression and Cell-Based Assays. The proteomics product addresses a major barrier in defining the function of proteins in cells; how to quickly and cheaply test thousands of samples for the presence of a particular set of proteins. This protein product will be closely followed by the launch of gene expression products to solve a similar barrier in the genomics market; how to quickly and cheaply interrogate thousands of samples against a defined set of important genes.
Shamrock Structures is a structural proteomics company focused on assisting pharmaceutical and biotechnology clients reduce the time it takes to advance from protein targets to drugs by offering integrated services in structural proteomics including protein cloning, expression, purification and crystallization.
The firm aims to provide powerful tools based on microelectronic technology to scientists involved in basic molecular biology research. Investigating the biological actions of molecules "in vitro" on cultured cells is a fundamental step for drug development and for basic life sciences. Routine techniques for intracellular delivery are high-cost and time-consuming procedures involving the use of a large amount of the candidate molecule and a stochastic interpretation of the results. Thanks to an combination of cell and molecular biology with semiconductor technology the company developed a new technique overcoming these limitations.
Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.